- Home
- OCGN
OCGN
Ocugen Inc.
as 01-02-2025 9:55am EST
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 246.8M | IPO Year: | N/A |
| Target Price: | $5.67 | AVG Volume (30 days): | 5.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.49 - $2.10 | Next Earning Date: | 11-08-2024 |
| Revenue: | $4,700,000 | Revenue Growth: | -33.94% |
| Revenue Growth (this year): | -38.82% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Ocugen Inc. (OCGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Castillo Kirsten | OCGN | Director | Nov 22 '24 | Buy | $0.91 | 25,000 | $22,847.50 | 75,000 |
Latest Ocugen Inc. News
OCGN Breaking Stock News: Dive into OCGN Ticker-Specific Updates for Smart Investing
Zacks
10 days ago
5 Biotech Breakthrough Stocks to Watch in 2025
MT Newswires
14 days ago
Ocugen Secures Data and Safety Monitoring Board Approval to Advance OCU410 Trial for Geographic Atrophy
GlobeNewswire
14 days ago
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
GlobeNewswire
22 days ago
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
GlobeNewswire
a month ago
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
MT Newswires
a month ago
Ocugen's Eye Disease Treatment Receives Orphan Drug Designation in Europe for Retinopathies
GlobeNewswire
a month ago
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
GlobeNewswire
a month ago
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Compare OCGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCGN Ocugen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.